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Genome-wide association studies have identiﬁed a number of signals for both Type 2 Diabetes and related
quantitative traits. For the majority of loci, the transition from association signal to mutational mechanism
has been difﬁcult to establish. Glucokinase (GCK) regulates glucose storage and disposal in the liver
where its activity is regulated by glucokinase regulatory protein (GKRP; gene name GCKR). Fructose-6
and fructose-1 phosphate (F6P and F1P) enhance or reduce GKRP-mediated inhibition, respectively.
Ac o m m o nGCKR variant (P446L) is reproducibly associated with triglyceride and fasting plasma glucose
levels in the general population. The aim of this study was to determine the mutational mechanism respon-
sible for this genetic association. Recombinant human GCK and both human wild-type (WT) and P446L-GKRP
proteins were generated. GCK kinetic activity was observed spectrophotometrically using an NADP
1-coupled
assay. WT and P446L-GKRP-mediated inhibition of GCK activity and subsequent regulation by phosphate
esters were determined. Assays matched for GKRP activity demonstrated no difference in dose-dependent
inhibition of GCK activity or F1P-mediated regulation. However, the response to physiologically relevant
F6P levels was signiﬁcantly attenuated with P446L-GKRP (n 5 18; P   0.03). Experiments using equimolar
concentrations of both regulatory proteins conﬁrmed these ﬁndings (n 5 9; P < 0.001). In conclusion,
P446L-GKRP has reduced regulation by physiological concentrations of F6P, resulting indirectly in increased
GCK activity. Altered GCK regulation in liver is predicted to enhance glycolytic ﬂux, promoting hepatic glu-
cose metabolism and elevating concentrations of malonyl-CoA, a substrate for de novo lipogenesis, provid-
ing a mutational mechanism for the reported association of this variant with raised triglycerides and lower
glucose levels.
INTRODUCTION
A recent genome-wide association (GWA) scan identiﬁed
GCKR as a potential locus for modulating triglyceride and
fasting plasma glucose (fpg) levels (1). GCKR encodes
glucokinase regulatory protein (GKRP), and following ﬁne
mapping attributed the signal to the common non-synonymous
SNP rs1260326 (c.1403 C . T, p.P446L, MAF 34%) (2). Sub-
sequent population-based studies have replicated the
association of this variant with triglyceride and fpg levels.
Individuals homozygous for the risk allele (L) have on
average a 0.15 mmol/l increase in triglyceride and a
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with two copies of the wild-type (WT) allele (P) (2–4). The
mutational mechanism behind this genetic association is cur-
rently unknown. However, unlike many signals arising from
GWA studies, there is a non-synonymous SNP in a strong bio-
logical candidate gene driving the genetic association, thus
facilitating functional studies. Even with such tractable var-
iants, identifying the mutational mechanism for common risk
alleles presents a challenge due to their small physiological
effects. It is therefore essential that the ‘correct’ assays are
selected and performed if these small differences in protein
function are to be observed.
Glucokinase (GCK) is a key regulator of glucose storage
and disposal in the liver. GKRP regulates GCK activity com-
petitively with respect to the substrate glucose (5,6). GKRP
action is in turn controlled by the phosphate esters fructose
6- and fructose 1-phosphate (F6P and F1P), which compete
with each other for binding, and enhance or inhibit the
action of the regulatory protein, respectively (7–9).
There is some controversy in the literature as to whether
GKRP also regulates GCK in pancreatic b-cells (10–12).
The vast majority of studies state that GCKR is not expressed
in rodent b-cells (11,12). However, there is evidence from one
study that an alternatively spliced GCKR variant is expressed
in the b-cells of rodents and represents the major isoform in
this tissue (10). To date, no studies have been reported
which investigate GCKR expression in human pancreatic
islets.
Biological evidence to support the association of these phe-
notypes with the GCKR SNP comes from both cellular and
rodent models (13,14). Counter intuitively, Slosberg et al.
over expressed GCKR in the human liver cell line HepG2
and showed an increase in GCK activity and expression at
the protein level. From this, they suggested that GKRP as
well as inhibiting GCK activity, also has a paradoxical role
in extending GCK half-life by binding to and stabilizing the
enzyme, thus protecting it from degradation (14). This
ﬁnding is supported by data from both homo- and heterozy-
gous gkrp knockout mice which display a marked reduction
in gck expression and reduced GCK enzymatic activity
under saturating glucose concentrations (11). At least one
study has also shown that in vivo over-expression of gck in
rat hepatocytes led to a drop in plasma glucose levels with a
corresponding increase in circulating triglycerides (13). There-
fore, ﬁndings from both groups suggested that (i) GKRP
expression has a direct affect on GCK activity and (ii) there
is a link between GCK activity and plasma glucose/circulating
triglyceride levels.
A number of studies investigating the interaction of GCK
and its regulatory protein have been reported but due to tech-
nical difﬁculties in purifying human recombinant GKRP, all of
these have used the rat isoform (9,15,16). One of these studies
investigated the effect of rodent P446L-GKRP on GCK
activity and reported no differences in the inhibitory ability
of the variant protein or its response to phosphate esters com-
pared with WT (9). However, despite their high sequence
homology (88%), there are important differences in the
regulation of rat and human GKRP (7,17). First, human regu-
latory protein inhibits GCK even in the absence of F6P, an
affect not observed with the same concentration of rat
GKRP. Secondly, human regulatory protein was shown to
have a higher afﬁnity for this phosphate ester compared with
the rodent protein (7).
The aims of this study were therefore, ﬁrst, to investigate
the affect of both human WT and P446L-GKRP on human
GCK activity and secondly, to determine whether their regu-
lation by phosphate esters was altered. Finally, we aimed to
establish whether GCKR is expressed in human pancreatic
islets, and if so, to look at this expression relative to that
of GCK.
RESULTS
WT and P446L-GKRP both inhibit GCK activity
To assess the inhibitory function of our puriﬁed recombinant
human WT and P446L-GKRP proteins following heterologous
expression in Escherichia coli, one unit of each regulatory
protein was used in assays to study competitive inhibition
of GCK activity over a glucose concentration range
(0–100 mM). Figure 1A demonstrates that GCK activity is
inhibited with both GKRPs (each data point being plotted as
a percentage of the negative control in which GKRP was
absent and glucose concentration was 100 mM), establishing
that both WT and P446L proteins are functional. These
results also show no difference between the ability of WT
and variant regulatory protein to inhibit GCK in the absence
of the phosphate esters F1P and F6P.
To further compare GKRP activity, competitive inhibition
assays were repeated at ﬁxed concentrations of both GKRP
proteins (n ¼ 3) as shown in Figure 1B (100 nM GKRP) and
C (150 nM GKRP). These data also demonstrate no difference
between the two regulatory proteins at 100 nM. However, at
150 nM, P446L-GKRP is less inhibitory than WT at concen-
trations of 25 mM glucose and above (P   0.03). Ki (inhibitor
dissociation constants) were calculated from Dixon plots of 1/
GCK activity versus [GKRP] for the equimolar concentration
experiments (Supplementary Material, Fig. S1). The Ki values
did not signiﬁcantly differ between the two regulatory
proteins (24.0+40.7 nM for WT versus 23.1+40.8 nM for
P446L-GKRP; mean+SEM; P ¼ 1).
Our data are consistent with GKRP acting as a competitive
inhibitor of GCK activity (18). The KcatGCK (maximal speciﬁc
activity of GCK) remained unchanged in the presence of 0–
150 nM regulatory protein (51.8+1.6 to 51.9+6.9 for WT
versus 46.8+0.7 to 53.4+3.6 for P446L-GKRP; n ¼ 3),
and the S0.5 (glucose concentration needed for half maximal
rate) was raised with increasing concentrations of both
GKRPs (8.7+0.2 to 16.8+1.3 for WT versus 8.0+0.3 to
18.2+1.1 for P446L-GKRP).
F1P increases GCK activity with both WT
and P446L-GKRP
Data obtained using comparable activities of regulatory
protein demonstrated the expected reduction in
GKRP-mediated inhibition of GCK activity across a F1P con-
centration range of 0–500 mM (Fig. 2A). This GKRP-mediated
inhibition was decreased by the same extent for both WT and
P446L-GKRP (53.7+1.1 to 92.8+1.2% GCK activity for
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P446L; means+SEM; n ¼ 18; P . 0.1).
Experiments using ﬁxed concentrations of both WT and
variant regulatory protein conﬁrmed that there was no differ-
ence in F1P-mediated inhibition of the two GKRPs at concen-
trations up to and including 500 mM of phosphate ester
(92.5+2.6% for WT versus 90.1+1.8% for P446L; n ¼ 9;
P ¼ 0.2), despite the initial difference in intrinsic inhibitory
capacity at 0 mM F1P (Fig. 2B).
It has been suggested previously that F1P causes an increase
in GCK activity by promoting dissociation of the GKRP:GCK
complex (7). Therefore the ‘apparent’ inhibitor dissociation
constant (Kiapparent) would be expected to increase upon
addition of F1P, as regulatory protein dissociation from the
enzyme is promoted. In our studies, Kiapparent from Dixon
plots of 1/GCK activity versus [F1P] reﬂected this. Also,
these calculated Kiapparent values did not signiﬁcantly differ
between the two regulatory proteins when using either com-
parable activity (24.5+2.0 mM for WT versus 31.2+
4.3 mM for P446L-GKRP; P ¼ 0.1) or equimolar concen-
trations (54.0+10.8 mM for WT versus 46.3+4.2 mM for
P446L-GKRP; P ¼ 0.5), suggesting a similar dissociation of
both regulatory proteins from GCK in response to F1P. This
was also corroborated by observing the [F1P] that caused
reversal of GCK inhibition by half (i.e. 75% enzyme activity),
which was 15 mM F1P for both GKRPs in the matched
activity experiments, and 15 and 20 mM F1P for P446L
and WT-GKRP, respectively, in the comparable concentration
experiments.
Differences in F6P-mediated regulation of P446L-GKRP
compared with WT
GCK activity was observed over 0–500 mM F6P in the pres-
ence of either equal activities or equivalent concentrations of
both GKRPs (Fig. 3A and B, respectively). It is well estab-
lished that F6P-mediated regulation of GKRP leads to
enhanced GCK inhibition, and hence a corresponding
reduction in observed enzyme activity (7,9,18). This was
seen with both WT and P446L-GKRP when using the same
activity of regulatory protein, although the reduction in GCK
activity was signiﬁcantly less over the physiologically relevant
25–500 mM F6P concentration range with the variant protein
(31.9+2.6 to 23.3+1.0% GCK activity versus 28.5+2.8
to 21.2+0.8% GCK activity for WT; means+SEM; n ¼
18; P ¼ 0.04, 0.0001, 0.006 and 0.03 for 25, 50, 100 and
500 mM F6P, respectively) (Fig. 3A).
Figure 1. (A) Competitive inhibition of GCK using equivalent activities of WT and P446L-GKRP (n ¼ 24). Competitive inhibition of 10 m U/ml GCK by one
GKRP unit (WT¼black circles, P446L¼white circles, negative control¼black triangles) was observed over a glucose concentration range of 0–100 mM. Each
data point was plotted as a percentage of the negative control in which GKRP was absent and glucose concentration equaled 100 mM. Statistical analysis revealed
no difference between the intrinsic inhibitory capacity of WT and P446L-GKRP. (B and C) Competitive inhibition of GCK using equimolar concentrations of
WT and P446L-GKRP (n ¼ 3). GCK activity was assayed in the presence of 0, 100 and 150 nM WT (black circles) and P446L (white circles) GKRP, over a
glucose concentration range of 0–100 mM. Each data point was plotted as a percentage of the negative control in which GKRP was absent (black triangles) and
glucose concentration equaled 100 mM. At 100 nM GKRP, there was statistically no difference between the responses of the two regulatory proteins (although it
was noted that the variance of this data was larger than seen for other experiments and n ¼ 3). At 150 nM GKRP, statistical analysis showed the intrinsic inhibi-
tory capacity of P446L-GKRP to be signiﬁcantly lower than that of the WT regulatory protein at [glucose] over 25 mM (P   0.03).
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concentration of both regulatory proteins, as there was a sig-
niﬁcant difference between the response of WT and
P446L-GKRP over the entire F6P concentration range
(63.7+2.6 to 14.1+1.2% versus 71.9+1.4 to 33.8+
3.1%, respectively; n ¼ 9; P , 0.001) (Fig. 3B).
Increasing F6P concentration has been shown in this study
to enhance GKRP-mediated inhibition of GCK activity, and
thus it would be expected that Kiapparent would be
decreased as a result of reduced dissociation of the inhibitor
GKRP from GCK (i.e. ‘tighter’ enzyme:regulatory protein
binding). This was reﬂected in our data, as Dixon plots of
[F6P] versus 1/GCK activity showed a decrease in Kiapparent
upon addition of F6P. Kiapparent was also signiﬁcantly different
between WT and P446L-GKRP for both the equal activity
(31.0+4.4 mM versus 21.1+2.7 mM, respectively; P ¼ 0.5)
and equimolar concentration experiments (16.6+1.7 mM
versus 9.2+1.0 mM, respectively; P , 0.001). The IC50
(concentration of F6P needed to inhibit enzyme activity
by 50%) was also signiﬁcantly different between WT
and P446L-GKRP; 23.8 versus 35.0 mM, respectively, for
matched activity experiments (P ¼ 0.01), and 25.0 versus
56.3 mM, respectively, for equal concentration experiments
(P , 0.001), reﬂecting a decreased afﬁnity of the variant
regulatory protein for F6P in both experiments.
GCKR is highly expressed relative to GCK in human liver,
with very low levels in human pancreatic islets
Owing to the association of P446L-GKRP with fpg levels, we
investigated whether the observed modulation in the
P446L-GKRP response to physiologically relevant F6P con-
centrations could have consequent metabolic affects in
human pancreatic islets as well as human liver. To address
this question, we quantiﬁed GCKR and GCK mRNA
levels in appropriate human tissues. Quantitative reverse
Figure 2. (A and B) F1P negatively modulates both WT and P446L-GKRP-mediated inhibition of GCK, leading indirectly to an increase in enzyme activity.
Inhibition of 10 m U/ml GCK by (A) one GKRP unit, 5 mM glucose (n ¼ 18) and (B) 100 nM GKRP, 10 mM glucose (n ¼ 3) was observed over 0–500 mM F1P
(black circles¼WT, white circles¼P446L). GCK activity was plotted as a percentage of that obtained in the absence of either regulatory protein. Statistical
analysis revealed no difference in response of WT and P446L-GKRP to F1P up to and including 500 mM F1P (P   0.1). Kiapparent from Dixon plots of [F1P]
versus 1/GCK activity did not signiﬁcantly differ between the two regulatory proteins (A) 31.2+4.3 mM for WT versus 24.9+2.0 mM for P446L-GKRP,
(B) 54.0+10.8 mM for WT versus 46.3+4.2 mM for P446L-GKRP; mean+SEM; P   0.1.
Figure 3. (A and B) F6P-mediated regulation of P446L-GKRP is signiﬁcantly diminished compared with WT regulatory protein. Inhibition of 10 m U/ml GCK
by (A) one unit GKRP, 5 mM glucose (n ¼ 18) and (B) 100 nM GKRP, 10 mM glucose (n ¼ 3) was observed over 0–500 mM F6P (black circles¼WT, white
circles¼P446L). GCK activity was plotted as a percentage of that obtained in the absence of regulatory protein. Statistical analysis showed there to be a sig-
niﬁcant difference between the response of WT and P446L-GKRP (A) over the physiologically relevant range 25–500 mM F6P (31.9+2.6 to 23.3+1.0% GCK
activity for P446L versus 28.5+2.8 to 21.2+0.8% GCK activity for WT; means+SEM; P ¼ 0.04, 0.0001, 0.006 and 0.03 for 25, 50, 100 and 500 mM F6P,
respectively) and (B) over the entire 0–500 mM F6P range (P , 0.001). Dixon plots of [F6P] versus 1/GCK activity showed Kiapparent was also signiﬁcantly
different between WT and variant regulatory protein in both (A) the comparable activity (31.0+4.4 versus 21.1+2.7 mM, respectively; P ¼ 0.05) and (B) equi-
molar concentration experiments (16.6+1.7 versus 9.2+1.0 mM, respectively; P , 0.001).
4084 Human Molecular Genetics, 2009, Vol. 18, No. 21transcription–polymerase chain reaction (qRT–PCR) analysis
of liver (n ¼ 1), islets (n ¼ 2), whole pancreas (n ¼ 1) and adi-
pocytes (n ¼ 1) demonstrated that GCKR mRNA is expressed
in molar excess in human liver compared with GCK, thus sup-
porting a functional role for the regulatory protein in the hep-
atocyte (19). Conversely, although GCKR is expressed at very
low levels in human islets, whole pancreas and adipocytes
(only a tenth of that seen in liver), the much higher relative
expression of GCK suggests regulation of this enzyme in
these tissues is largely not GKRP mediated (Fig. 4).
DISCUSSION
In this study, we have performed the ﬁrst functional character-
ization of the human P446L-GCKR variant, which has been
reproducibly associated with an average 0.15 mmol/l increase
in triglyceride and a 0.06 mmol/l decrease in fpg levels in the
general population (1–4). Our data demonstrate both human
WT and variant regulatory protein to be functional and able
to inhibit GCK activity in a dose-dependent manner. Both
GKRPs were also equally sensitive to F1P-mediated regu-
lation, which is consistent with that shown previously using
rodent proteins (16). However, our analyses have revealed a
previously unappreciated change in F6P-mediated modulation
of the P446L regulatory protein at physiologically relevant
concentrations of this phosphate ester. These results differ
from those reported in earlier rodent studies which showed
no differences between the two proteins and conﬁrm the
important differences in the properties of human GKRP com-
pared with rodent homologues (7).
The differing responses of the P446L-variant regulatory
protein to F1P and F6P may be explained by looking at the
binding site of these molecules. The crystal structure of
GKRP has not been solved; however, it does have homology
with other proteins of known crystal structure, such as the iso-
merase domain of bacterial glucosamine 6-phosphate synthase
(GlmS), which catalyses the conversion of F6P into either
glucose 6-phosphate or glucosamine 6-phosphate (9,20–22).
This isomerase domain consists of two sugar isomerase sub-
domains (23), and analysis of the GlmS crystal structure
(21) and functional studies on rat GKRP mutants (9) suggests
a single substrate binding site lies between the interface of
these two sub-domains. It has also been suggested that
GKRP adopts different structural conformations in order to
accommodate either F1P or F6P at this single binding site,
and only one of these (that favoring F6P-binding) can
complex with GCK (9,24). Residue 446 lies between two
sequence motifs thought to be involved directly in binding
of phosphate esters. As previously reported, mutating certain
residues outside of these motifs can still affect binding (and
hence regulation of GKRP activity) (9). Also, residue 446 is
a conserved proline across human, rat and Xenopus laevis
regulatory protein, and all bar the latter are responsive to
both F1P and F6P (7,9). Therefore, we propose that residue
446 may not play a direct role in the binding of phosphate
esters, but may be important structurally within GKRP. This
amino acid substitution could then either reduce the ability
of the regulatory protein to adopt the F6P-binding confor-
mation or hinder the F6P–GKRP complex from binding to
and inhibiting GCK.
Our data show F6P-mediated regulation of P446L-GKRP to
be signiﬁcantly attenuated compared with WT over a physio-
logical range of F6P concentrations, which ultimately leads to
a reduction in GCK-inhibition by the variant regulatory
protein. This is predicted to increase glycolytic ﬂux and
hence glucose uptake by the liver. This enhanced rate of gly-
colysis (as is seen with GCK over-expression in rats) may
raise levels of other liver metabolites such as malonyl-CoA,
increasing triglyceride levels via two mechanisms; ﬁrst by
acting as a substrate for de novo lipogenesis and secondly
by inhibiting carnitine-palmitoyl transferase-1 (thus blocking
fatty acid oxidation) (13). This perturbation of hepatic metab-
olism could account for the reduced glucose and raised trigly-
cerides seen in L446-GKRP individuals. However, the very
low GCKR mRNA levels detected in human islets (compared
with human liver) suggest that GKRP has only a very minor (if
any) functional role in the regulation of GCK in the pancreas.
Consequently, pancreatic GCK is unlikely to be affected in
individuals with this variant regulatory protein conﬁrming
that the phenotype observed is driven by a hepatic effect.
Broader implications of these ﬁndings regard the alteration
of GCK activity to treat diabetes. Aberrant GCK function has
been implicated in both monogenic forms of diabetes and in
the variation of fpg levels within the general population, and
as such it is a well-established therapeutic target (25,26).
The initial genetic association data concerning the
P446L-GCKR variant (1–4) supported by our functional
studies conﬁrm that changing the regulation of GCK activity
solely in the liver could alter other hepatic metabolic path-
ways, thus resulting in an unfavorable lipid proﬁle. This has
Figure 4. GCKR and GCK expression in human liver, pancreas, isolated islets,
adipocytes, skeletal muscle and kidney. One microgram RNA was converted
to cDNA via RT–PCR and expression of the human GCKR and GCK genes
observed via Taqman gene expression analysis. Liver (n ¼ 1), islets (n ¼ 2),
pancreas (n¼1) and adipocytes (n ¼ 1) were studied (as well as appropriate
negative controls). These data show GCKR to be highly expressed in molar
excess in the liver compared with GCK. However, in the pancreas and
islets, GCK levels are much higher than that of the regulatory protein. In adi-
pocytes, skeletal muscle and kidney both genes are only present at negligible
levels.
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over-expressing hepatic gck lowers plasma glucose as well
as raising triglyceride levels (13). However, a number of
other studies have shown that hepatic over-expression of gck
does not always result in an increase in triglycerides,
suggesting that the degree of increased gck activity is critical
(27,28). As such, potential new therapies targeting GKRP in
the liver should be approached with caution.
In conclusion, our functional studies demonstrate that
altered F6P-mediated GKRP regulation in carriers of the
L446 allele explains the association between the common
P446L-GCKR variant and higher triglyceride and lower fpg
levels in several human populations. This work demonstrates
that with suitable functional studies it is possible to establish
mutational mechanisms for common variants of modest
effect size identiﬁed by GWA studies.
MATERIALS AND METHODS
Site-directed mutagenesis
p-FLAG CTC vector (Sigma Aldrich Company Ltd,
Gillingham, UK) containing human GKRP coding sequence
was kindly supplied by Katy Brocklehurst (7). The P446L
mutation was introduced via PCR-based site-directed muta-
genesis using Pfu-polymerase (Promega, Southampton, UK)
and primers shown in Supplementary Material, Table S1
(Operon Biotechnologies GmbH, Cologne, Germany).
Mutant and WT plasmids were then used to transfect BL21
competent cells (Stratagene Europe, Amsterdam, The Nether-
lands), and DNA obtained using QIAprep Spin Miniprep Kit
(Qiagen Ltd, Crawley, UK). Mutant and WT sequences were
conﬁrmed via direct sequencing using primers in Supplemen-
tary Material, Table S2.
Protein extraction
Glutathione S-transferase-tagged human pancreatic GCK was
prepared as described previously (29). The pancreatic
isoform was used as it has the same afﬁnity for GKRP as
liver GCK (30). The extracted enzyme was pure and at a
concentration of 1.2 mg/ml, as determined by the Agilent
230 Protein kit (Agilent Technologies UK Ltd, Stockport,
UK) and Bio-Rad Bradford reagent assay (Bio-Rad Labora-
tories Ltd, Hemel Hempstead, UK), respectively. Three prep-
arations each of FLAG-tagged human WT and P446L-GKRP
were extracted based on a protocol previously described but
without the use of a DEAE-sepharose ion-exchange resin
(7). The extracted regulatory proteins were conﬁrmed as
being greater than 95% pure via Agilent analysis, and concen-
trations quantiﬁed as before (average 0.19 mg/ml for WT and
0.12 mg/ml for P446L-GKRP; n ¼ 3). Storage buffer [0.7 M
glycerol, 0.2 M KCl, 0.06 M Tris–HCl (pH 8), 5 mM dithio-
threitol (DTT), 0.06 M glucose (GCK preparation only); all
Sigma Aldrich Company Ltd] was added to recombinant
GCK and GKRP in 1:1 volume ratio prior to snap-freezing
and storage at 2808C. For initial regulatory protein prep-
arations (n ¼ 1), storage buffer including glucose was added
to samples. As this affected competitive inhibition assays,
storage buffer was changed using Vivaspin20 columns
containing diaﬁltration cups (Sartorius Mechatronics, Epsom,
UK) to one in which glucose was absent.
GKRP assays
GKRP inhibition of GCK activity was determined spectropho-
tometrically using glucose 6-phosphate dehydrogenase
(G6PDH)-linked assays (Sigma Aldrich Ltd). Experiments
using both comparable activity/mg (amount of WT and
P446L-GKRP used in each experiment inhibited 10 m U/ml
GCK by the same extent at 5 mM glucose in the absence of
the phosphate esters) (7) and equimolar concentrations
(either 0, 50, 100 or 150 mM of both regulatory proteins
used per assay) (9) were conducted. Assays were based on pre-
viously described protocols (7,29,30) but with the following
modiﬁcations. Competitive inhibition assays were at 378C,
pH 7.1, and contained 2 mM MgCl2, 3.8 mM bovine serum
albumin, 25 mM KCl, 25 mM HEPES, 0.5 mM NADP
þ,1m M
ATP, 1 mM DTT, 0–100 mM glucose, 4 U/ml G6PDH,
10 m U/ml GCK and 1 U GKRP. All assay reagents (except
GCK and GKRP which were generated in-house) were
obtained from Sigma Aldrich Ltd. One m-unit of GCK was
deﬁned as that which converts 1 nmol substrate per minute,
whereas one GKRP unit was deﬁned as that which inhibits
10 m U/ml GCK by 50% under the standard assay conditions
deﬁned above (7). On average at 5 mM glucose, one GKRP
unit resulted from 15.87 mg/ml of WT and 14.05 mg/ml of
P446L-GKRP (n ¼ 3 independent protein preparations). One
GKRP unit of both WT and variant P446L regulatory
protein were subsequently used per equimolar activity assay.
F1P and F6P assays were performed using the same assay
conditions as for competitive inhibition experiments, but
only 5 mM glucose (7). Both phosphate esters were purchased
from Sigma Aldrich Ltd.
Ki (inhibitor dissociation constants) were determined from
Dixon plots of 1/GCK activity versus [GKRP] as previously
described (7) for the competitive inhibition assays. Plots of
1/GCK activity versus [F6P] or [F1P] were also used to deter-
mine apparent inhibitor dissociation constants, ‘Kiapparent’,
from these experiments. As the phosphate esters are secondary
regulators of GCK activity (act via the inhibitor GKRP),
Dixon plots provided an insight into dissociation of the phos-
phate esters, GKRP and GCK, but could not be used to dis-
tinguish speciﬁcally between the individual components of
these interactions.
Gene expression analysis
GCKR and GCK expressions were observed via qRT–PCR in
human liver (n ¼ 1), human islets (n ¼ 2), human pancreas
(n ¼ 1) and human adipocytes (n ¼ 1). All samples were
part of a commercially available human RNA tissue panel
(Clontech-Takara Bio Europe, Saint-Germain-en-Laye,
France), except for the human islets which were collected as
part of a previous study at Oxford University which had
been conducted with full ethical consent. RNA samples were
initially treated with DNase I (Applied Biosystems, Warring-
ton, UK) to remove all genomic contamination. This was fol-
lowed by random primed ﬁrst-strand cDNA synthesis using
1 mg of each RNA sample and a High Capacity cDNA
4086 Human Molecular Genetics, 2009, Vol. 18, No. 21Reverse Transcription Kit (Applied Biosystems). Reactions in
which the enzyme was absent were also carried out to produce
negative controls for the ﬁnal qRT–PCR. cDNA was diluted
1/100 and 4 ml used in a total reaction volume of 10 ml
[5.5 ml of Taqman gene expression master mix and 0.5 mlo f
the appropriate Taqman gene expression assay (both Applied
Biosystems)] and each sample run in triplicate. GCKR and
GCK expressions were made relative to three house-keeping
genes (HPRT, B2M and ACTB), and normalized to the 1/100
dilution of the standard curve (for each gene-speciﬁc assay).
Statistical analysis
Paired two-tail t-tests were used for statistical analysis of
all assay data, with a cut-off value for statistical signiﬁcance
of 0.05.
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